Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall…
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer,…